Biogen Guidance Raise Begins to Validate Growth Portfolio, Easing MS Erosion Fears

What happened

Biogen reported second-quarter results and raised full-year earnings guidance, citing strength in its growth portfolio that includes the Alzheimer’s drug LEQEMBI and newly acquired Apellis assets. The improved outlook exceeded cautious expectations that had been shaped by ongoing legacy multiple sclerosis declines and integration uncertainty. The raise signals that the Apellis acquisition is contributing accretively and that Alzheimer’s franchise revenue is scaling, partially offsetting erosion from older drugs like TECFIDERA. Management has now provided the first Apellis-inclusive guidance that supports its 2027 EPS accretion target, a key proof point the market had been awaiting. With this print, the transition narrative gains credibility, though full margin and cash-flow details will not be clear until the 10-Q filing.

Implication

The Q2 raise marks a critical milestone, showing the growth portfolio can absorb legacy declines. Investors should watch for margin quality and LEQEMBI SC approval on Aug 24 to confirm sustained momentum. Near-term price may move toward the $215 base case; pullbacks toward $185 become attractive if the growth narrative holds.

Thesis delta

The July 29 print shifts the risk-reward from WAIT toward a more constructive stance. Apellis-driven guidance raise and LEQEMBI momentum begin to substantiate the 2027 EPS accretion path. The next test is the August 24 FDA decision on LEQEMBI subcutaneous initiation.